IP Group plc
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- IP Group plc (IPO.L) is a United Kingdom-based early-stage science investor that develops and supports businesses in deep technology, life sciences, and clean technology through commercialization of intellectual property from partner universities and research institutions; it provides seed, early venture, emerging growth, and later-stage capital across stages including incubation and mezzanine financing, alongside strategic guidance, mentorship, and management of third-party funds such as the IP Group Hostplus Innovation Fund; core portfolio companies include Oxford Nanopore Technologies plc, First Light Fusion, Hysata, Oxa, Apollo Therapeutics, Genomics plc, and Istesso, with focus areas encompassing applied AI (particularly cybersecurity), next-generation networks, human-machine interfaces, future compute, renewable electricity, alternative fuels, mobility, greenhouse gas capture, climate risk management, sustainable agriculture, and innovative therapies like obesity drug candidates. The company operates primarily from its headquarters at 2nd Floor, 3 Pancras Square, Kings Cross, London, England N1C 4AG, with additional offices in Australia and Asia, targeting high-growth innovators in the UK, Australia, and global markets; founded in 2001 as a public limited company listed on the London Stock Exchange, it functions under SIC code 64303 for venture and development capital activities, segmented into Healthier Future, Tech-enriched Future, Regenerative Future, and other thematic investments. Recent developments include potential royalty revenues from portfolio-derived obesity drug candidates licensed to Metsera Inc., acquired by Pfizer for up to $7.3 billion in 2025 with IP Group eligible for tiered low single-digit percentages on net sales plus milestones shared with Imperial College London; in 2023-2024, it committed US$15 million to Hysata's funding round at a substantial valuation uplift, invested £15 million in Istesso's convertible note (followed by £10 million in January 2024), supported portfolio fundings like Accelercomm's £21 million Series B, Quantum Motion, Apollo Therapeutics' $226.5 million Series C, and Genomics plc's £35 million round, launched support for Lumai's $10 million+ AI optical compute raise in 2025 led by Constructor Capital, and manages A$310 million in the Hostplus fund investing in scale-up companies including Oxford Nanopore and Oxa.
Company News
IP Group cheers investor interest in spin-outs, calls for more supportive Govt backing
IP Group leads funding round for University of Liverpool AI spin-out Matter Machine
IP Group banks £21m in Oxford Nanopore divestment
IP Group Plc (IPZYF) Q2 2026 Earnings Call Transcript
IP Group H1 Earnings Call Highlights
Top investor Railpen walks away from UK's IP Group
Frontier IP Group: Cambridge Raman Imaging secures €400,000 European grant
IP Group board may struggle to back sweetened Railpen offer, says Deutsche Bank
Mach42 Completes £7M Funding Round, Led by IP Group With Investment From BGF and Foresight Group
UK's IP Group rebuffs Railpen's revised 71.3 pence proposal
Railpen lifts IP Group offer with cash, Nanopore stake and Metsera upside
UK's IP Group gets sweetened takeover offer from top investor Railpen
IP Group rejects Railpen takeover proposal as too low
Deutsche Bank unsurprised by IP Group's rejection of Railpen approach
IP Group rejects takeover approach from its biggest shareholder
IP Group's Istesso starts phase II trial of leramistat in sarcopenia
IP Group portfolio company Enterprise Therapeutics reports positive phase II results in cystic fibrosis
IP Group portfolio company Enterprise Therapeutics reveals positive cystic fibrosis trial results
IP Group appoints former 3i chief as incoming chair
Lindian secures US$11.6M facility with Malawian bank to support Kangankunde ramp-up